Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis B news

Show

From To
WHO guidelines on hepatitis B and C testing

These are the first WHO guidelines on testing for chronic HBV and HCV infection and complement published guidance by WHO on the prevention, care and treatment of chronic hepatitis C and hepatitis B infection. These guidelines outline the public health approach to strengthening and expanding current testing practices for HBV and HCV, and are intended for use across age groups and populations.

Published
21 February 2017
From
World Health Organization
Tenofovir alafenamide approved for hepatitis B in Europe

The European Commission this week granted marketing authorisation for tenofovir alafenamide, to be sold under the brand name Vemlidy, for the treatment of chronic hepatitis

Published
17 January 2017
By
Liz Highleyman
European Commission Grants Marketing Authorization for Gilead’s Vemlidy® (Tenofovir Alafenamide, TAF) for the Treatment of Chronic Hepatitis B Virus Infection

Vemlidy® is the First New Treatment for Chronic Hepatitis B Infection to be Approved in the European Union in Nearly a Decade

Published
12 January 2017
From
Gilead press release
Tenofovir alafenamide approved for hepatitis B, works well with less effect on bones

Tenofovir alafenamide (TAF), a new lower-dose pro-drug, matches the older tenofovir disoproxil fumarate (TDF) for antiviral activity against hepatitis B virus (HBV) but causes less bone mineral loss,

Published
15 November 2016
By
Liz Highleyman
U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy® (tenofovir alafenamide, TAF) 25mg, a once-daily treatment for adults with chronic hepatitis B virus (HBV) infection with compensated liver disease.

Published
11 November 2016
From
Gilead press release
Hepatitis B testing should be done before hepatitis C treatment due to risk of HBV reactivation

People considering direct-acting antiviral (DAA) therapy for hepatitis C should first be tested for hepatitis B virus (HBV) and monitored throughout therapy, as elimination of hepatitis C virus

Published
07 October 2016
By
Liz Highleyman
HCV Drugs May Reactivate HBV, FDA Warns

Patients with a past or current hepatitis B virus (HBV) infection can experience sometimes fatal HBV reactivation if they take any of nine direct-acting antivirals for hepatitis virus C (HCV) infection, the US Food and Drug Administration (FDA) announced today.

Published
06 October 2016
From
Medscape (free registration required)
ContraVir Reports New CRV431 Data Highlighting Synergistic Activity with CMX157 Against Hepatitis B

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, today announced that it has taken a major step forward in its pursuit of a potentially curative combination therapy for chronic hepatitis B (HBV).

Published
12 September 2016
From
ContraVir press release
Act now for a Hepatitis-free Indonesia

In the archipelago, hepatitis B is a virus that affects around 28 million people, or roughly around 10 percent of the population, with 14 million people at risk of the virus developing into chronic cirrhosis or liver failure.

Published
07 September 2016
From
Jakarta Post
Improvements in HIV treatment and care have had no impact on rates of endstage liver disease among HIV-positive people with viral hepatitis

Incidence of endstage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from

Published
05 September 2016
By
Michael Carter
← First12345...16Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.